*Fraction of cetuximab OS benefit that is retained by panitumumab
• Panitumumab was assessed to be non-inferior to cetuximab for OS based on a
≥50% retention rate* of the OS benefit of cetuximab
• Actual OS retention rate was 106% (95% CI: 82%,130%)
Efficacy
Panitumumab
Cetuximab
Hazard/odds
ratio
Median
OS
,
months (95% CI)
10.4 (9.4, 11.6) 10.0 (9.3, 11.0)
HR=0.97
(0.84, 1.11)
Median PFS
,
months (95% CI)
4.1 (3.2, 4.8)
4.4 (3.2, 4.8)
HR =1.00
(0.88, 1.14)
ORR
, % (95% CI) 22.0 (18.4, 26) 19.8 (16.3, 23.6)
OR=1.15
(0.83, 1.58)
Peeters, et al. Lancet Oncology 2014
ASPECCT: efficacy of panitumumab versus cetuximab for previously treated
WT
KRAS
mCRC
